NCT06495164View on ClinicalTrials.gov

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

5,087

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Breast CancerMalignant Neoplasm of Breast

Interventions

DRUG

Palbociclib

CDK4/6 inhibitor

DRUG

Aromatase inhibitor

Aromatase inhibitor

DRUG

Ribociclib

CDK4/6 inhibitor

DRUG

Abemaciclib

CDK4/6 inhibitor

Trial Locations (1)

10001

RECRUITING

Pfizer New York, New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT06495164 - A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | Biotech Hunter | Biotech Hunter